Spots Global Cancer Trial Database for Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer
Official Title: A Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer
Study ID: NCT01215799
Conditions
Interventions
Study Description
Brief Summary: This is a Phase II open-label study evaluating the preliminary efficacy and safety of bafetinib administered as 240 mg orally twice daily in subjects with Hormone Refractory Prostate Cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
City of Hope Medical Center, Duarte, California, United States
Contact Details
Name: Daniel Levitt, M.D., Ph.D.
Affiliation: Chief Medical Officer, CytRx Corporation
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
